TP53 and cancer: PRMT5‐deficient cells exhibit induction of the p53 response, DNA damage, and cell death, and as such, PRMT5 is an interesting therapeutic target for many cancers (Chan‐Penebre et al, 2015; Koh et al, 2015; Li et al, 2015; Kaushik et al, 2018).